The revenue beat and guidance raise confirm accelerating momentum across both DSPS and NGS segments, with the company on track for Q4 adjusted EBITDA breakeven. The litigation settlement is a one-time charge that does not affect the underlying operational trajectory. Watch for continued NGS acceleration in H2 and any updates on the AWS partnership and Invenra licensing deal.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $56.19entry
- T+1 · 7mo ago +0.91%α +0.11% · $56.70
- T+5 · 6mo ago +0.04%α −2.90% · $56.21
- T+20 · 6mo ago +20.77%α +15.12% · $67.86
- T+60 · 4mo ago +52.11%α +50.25% · $85.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Twist Bioscience reported fiscal Q2 2026 revenue of $110.7M, a 19% YoY increase and above the prior quarter's $103.7M, while raising full-year FY2026 revenue guidance to $442M-$447M from $435M-$440M. GAAP net loss widened to $0.71/share from $0.66/share a year ago due to a $7.2M litigation settlement charge, but adjusted EBITDA improved to -$13.3M from -$14.8M. The company reiterated its Q4 FY2026 adjusted EBITDA breakeven target, and both DSPS (+28%) and NGS (+12%) segments showed strong growth.
Key Financial Metrics
Key Facts
- Q2 FY2026 revenue of $110.7M, up 19% YoY from $92.8M, exceeding the prior quarter's $103.7M and the company's own guidance
- Full-year FY2026 revenue guidance raised to $442M-$447M from $435M-$440M, implying 17%-19% YoY growth
- Q3 FY2026 revenue guided to ~$114M-$115M, ~19% YoY growth at the midpoint
- GAAP net loss per share was -$0.71 vs -$0.66 a year ago, including a $7.2M litigation settlement charge
- Adjusted EBITDA improved to -$13.3M from -$14.8M in the year-ago quarter
- DSPS revenue grew 28% YoY to $53.3M; NGS revenue grew 12% YoY to $57.4M
- Gross margin improved to 51.6% from 49.6% a year ago
- Cash and short-term investments stood at ~$172M as of March 31, 2026
- Company reiterated achieving adjusted EBITDA breakeven in Q4 FY2026
- Entered into a bispecific licensing agreement with Invenra and was named an AWS wet lab partner for Amazon Bio Discovery
Financial Impact
Revenue beat internal guidance by ~$2-3M; full-year guidance raised by $7M at the midpoint; net loss widened by $4.7M due to a $7.2M litigation charge
Risk Factors
- GAAP net loss widened to -$0.71/share, and the company remains unprofitable on a GAAP basis
- Cash burn continues, cash and short-term investments declined from $198M to $172M over the quarter
- Litigation settlement of ~$17.1M (with $7.2M booked this quarter) is a cash outflow risk
- Dependence on a single supplier for a critical component and potential supply chain disruptions
- Forward-looking statements on profitability and growth are subject to market conditions and execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001581280-26-000037 |
| Document: twist-20260504.htm | 0001581280-26-000037 |
| Document: 0001581280-26-000037-index-headers.html | 0001581280-26-000037 |
| Document: 0001581280-26-000037-index.html | 0001581280-26-000037 |
| Document: 0001581280-26-000037.txt | 0001581280-26-000037 |
| 8-K Data (Synthetic) | 0001581280-26-000037 |
Track record
47 reports on TWST
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +55.24% at T+60 after the Aug 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.03 Now $105.04 +0.01% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.16 Now $105.04 −0.11% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $104.98 Now $105.04 +0.06% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.61 Now $105.04 −0.54% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $104.03 Now $105.04 +0.98% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $114.22 Now $105.04 −8.04% settles Dec 11
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $114.22 Now $105.04 −8.04% settles Dec 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $132.13 Now $105.04 −20.50% settles Dec 9
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $120.79 Now $105.04 −13.04% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $120.61 Now $105.04 −12.91% settles Dec 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers